ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,705.55
      -0.14%
      US Tech 100
      19,286.80
      -0.25%
      Dow Jones
      42,092.57
      0.16%
      Brent Oil
      74.225
      -0.13%
      Bitcoin
      62,927.48
      -0.04%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Regeneron Pharmaceuticals Inc (REGN)

      7. Regeneron Pharmaceuticals Inc (REGN) News

      REGN

      Regeneron Pharmaceuticals (REGN)

      Regeneron Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:REGN
      DateTimeSourceHeadlineSymbolCompany
      09/20/20247:45AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year OldNASDAQ:REGNRegeneron Pharmaceuticals Inc
      09/13/202412:15PMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)NASDAQ:REGNRegeneron Pharmaceuticals Inc
      09/11/20247:00AMGlobeNewswire Inc.EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety ProfileNASDAQ:REGNRegeneron Pharmaceuticals Inc
      09/09/20245:00PMGlobeNewswire Inc.Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung CancerNASDAQ:REGNRegeneron Pharmaceuticals Inc
      09/09/20247:00AMGlobeNewswire Inc.Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMONASDAQ:REGNRegeneron Pharmaceuticals Inc
      09/05/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      09/05/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      09/05/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      09/03/20244:04PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/29/20244:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/28/20244:35PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/26/20247:00AMGlobeNewswire Inc.Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/26/20241:00AMGlobeNewswire Inc.Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/20/20246:45PMGlobeNewswire Inc.Regeneron Provides Update on Biologics License Application for LinvoseltamabNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/19/20244:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/19/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/15/20245:55PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/15/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/15/202411:45AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/14/20244:08PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/14/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/12/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/08/20244:53PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/07/20244:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/07/20244:33PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/07/20244:05PMGlobeNewswire Inc.Regeneron Announces Investor Conference Presentations and Oncology Investor WebcastNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/06/20244:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/05/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/05/20244:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
      08/05/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:REGN